Addressing Unmet Needs in the Management of AML: From Testing to Targeted Therapy

Insights from 2024 EHA Annual Meeting
E

EHA 2024 Insights: QuANTUM-First Trial - Newly Diagnosed FLT3-ITD+ AML Patients Receiving Chemo + Quizartinib vs. Placebo

By Insights from 2024 EHA Annual Meeting FEATURING Esther Oliva
By Insights from 2024 EHA Annual Meeting FEATURING Esther Oliva
114 views
June 28, 2024
0 Comments
Login to view comments. Click here to Login
23:51
Vanderbilt University Medical Center (VUMC)

Pre-Transplant Management of High-Risk AML

Feat. K. Fedorov
14:58
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Optimal Treatment Strategies for Younger P…

Feat. C. McMahon
21:05
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "The Art and Science of Caring for Older Ad…

Feat. K. Poh Loh
35:15
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: AML

Feat. F. Ravandi
35:08
MyCancerHaven

Experts Discuss the Role of Stem Cell Transplant in AML

Feat. R. Vij, M. Qazilbash
48:04
Icahn School of Medicine at Mount Sinai

Integrating Targeted Therapies in AML

Feat. H. Kantarjian
20:40
Rush University Medical Center

What is New in AML: Risk Classification, Germline Mutations, and Tar…

Feat. E. Atallah
04:16
UChicago Medicine 12th International Clinical Cancer Genomics Conference

MDS and AML: Implementation of Guideline-Driven Germline Genetic Eva…

Feat. L. Banaszak
17:01
Indy Hematology Review

R/R AML: Current, Emerging, and Targeted Therapies

Feat. R. Komrokji
17:51
Indy Hematology Review

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Feat. H. Erba
28:02
University of Colorado Division of Hematology

2024 Updates in AML

Feat. C. McMahon
06:13
Insights from 2023 ASH Annual Meeting

FLT3-ITD Mutated AML: PROs From the QuANTUM-First Trial of Quizartin…

Feat. E. Oliva
29:38
Scripps Health

FLT3-Mutated AML: Advances in Frontline Treatment

Feat. N. Short
07:56
University of Miami Sylvester Comprehensive Cancer Center

Role of Mutations in AML: FLT3-ITD Mutation Confers Poor Prognosis b…

Feat. S. Venugopal
18:27
Insights from 2023 ASH Annual Meeting

FLT3-ITD Mutated AML: QuANTUM-First - Safety by Treatment Phase and …

Feat. H. Erba
22:30
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Emerging Treatment Options for AML in 2024

Feat. A. Perl
22:37
Insights from 2023 ASH Annual Meeting

AML and MDS Highlights & Key Takeaways

Feat. T. Badar
10:32
Insights from 2023 ASH Annual Meeting

FLT3-ITD Mutated AML: Quizartinib, Venetoclax, & Decitabine Trip…

Feat. M. Yilmaz